title: The role of second autografts in the management of myeloma at first relapse.
abstract: We report an analysis of the value of a second high-dose melphalan autograft, performed at relapse, on a series of newly diagnosed myeloma patients entered into the high-dose program at our center. We conclude that relapse-free survival after the first autograft is a major prognostic factor in determining outcome.
authors.forename: Caroline L
authors.initials: CL
authors.lastname: Alvares
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.forename: Clive
authors.initials: C
authors.lastname: Horton
authors.forename: Gita
authors.initials: G
authors.lastname: Patel
authors.forename: Ray
authors.initials: R
authors.lastname: Powles
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D019468:Disease Management; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan